MX2021007019A - Derivados de xantina sustituida. - Google Patents
Derivados de xantina sustituida.Info
- Publication number
- MX2021007019A MX2021007019A MX2021007019A MX2021007019A MX2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A MX 2021007019 A MX2021007019 A MX 2021007019A
- Authority
- MX
- Mexico
- Prior art keywords
- xanthine derivatives
- substituted xanthine
- formula
- substituted
- trpc5
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212060 | 2018-12-12 | ||
| PCT/EP2019/084375 WO2020120450A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007019A true MX2021007019A (es) | 2021-09-10 |
Family
ID=64665184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007019A MX2021007019A (es) | 2018-12-12 | 2019-12-10 | Derivados de xantina sustituida. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11198696B2 (https=) |
| EP (1) | EP3894410B1 (https=) |
| JP (1) | JP7502299B2 (https=) |
| KR (1) | KR102877857B1 (https=) |
| CN (1) | CN113166151B (https=) |
| AU (1) | AU2019396499B2 (https=) |
| BR (1) | BR112021008316A2 (https=) |
| CL (1) | CL2021001509A1 (https=) |
| DK (1) | DK3894410T3 (https=) |
| EA (1) | EA202191588A1 (https=) |
| ES (1) | ES2964630T3 (https=) |
| HU (1) | HUE064908T2 (https=) |
| IL (1) | IL283768B2 (https=) |
| MX (1) | MX2021007019A (https=) |
| PH (1) | PH12021551345A1 (https=) |
| PL (1) | PL3894410T3 (https=) |
| TW (1) | TWI825243B (https=) |
| WO (1) | WO2020120450A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12064917B2 (en) | 2012-11-21 | 2024-08-20 | Stratasys, Inc. | Method for printing three-dimensional parts with cyrstallization kinetics control |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
| WO2024164818A1 (zh) * | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107082782B (zh) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| WO2016023830A1 (en) | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| DK3652176T3 (da) * | 2017-07-11 | 2022-01-17 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
-
2019
- 2019-12-10 HU HUE19820718A patent/HUE064908T2/hu unknown
- 2019-12-10 DK DK19820718.5T patent/DK3894410T3/da active
- 2019-12-10 WO PCT/EP2019/084375 patent/WO2020120450A1/en not_active Ceased
- 2019-12-10 CN CN201980081737.1A patent/CN113166151B/zh active Active
- 2019-12-10 PL PL19820718.5T patent/PL3894410T3/pl unknown
- 2019-12-10 AU AU2019396499A patent/AU2019396499B2/en active Active
- 2019-12-10 KR KR1020217021875A patent/KR102877857B1/ko active Active
- 2019-12-10 EA EA202191588A patent/EA202191588A1/ru unknown
- 2019-12-10 EP EP19820718.5A patent/EP3894410B1/en active Active
- 2019-12-10 MX MX2021007019A patent/MX2021007019A/es unknown
- 2019-12-10 JP JP2021533340A patent/JP7502299B2/ja active Active
- 2019-12-10 ES ES19820718T patent/ES2964630T3/es active Active
- 2019-12-10 PH PH1/2021/551345A patent/PH12021551345A1/en unknown
- 2019-12-10 IL IL283768A patent/IL283768B2/en unknown
- 2019-12-10 BR BR112021008316-2A patent/BR112021008316A2/pt unknown
- 2019-12-11 US US16/710,887 patent/US11198696B2/en active Active
- 2019-12-12 TW TW108145593A patent/TWI825243B/zh active
-
2021
- 2021-06-09 CL CL2021001509A patent/CL2021001509A1/es unknown
- 2021-11-10 US US17/523,316 patent/US20220177479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL283768A (en) | 2021-07-29 |
| IL283768B2 (en) | 2024-05-01 |
| HUE064908T2 (hu) | 2024-04-28 |
| US11198696B2 (en) | 2021-12-14 |
| DK3894410T3 (da) | 2023-11-27 |
| TWI825243B (zh) | 2023-12-11 |
| AU2019396499B2 (en) | 2024-10-10 |
| WO2020120450A1 (en) | 2020-06-18 |
| KR102877857B1 (ko) | 2025-10-29 |
| CA3119229A1 (en) | 2020-06-18 |
| CL2021001509A1 (es) | 2021-12-17 |
| KR20210102955A (ko) | 2021-08-20 |
| BR112021008316A2 (pt) | 2021-08-03 |
| CN113166151B (zh) | 2023-12-01 |
| EP3894410A1 (en) | 2021-10-20 |
| PH12021551345A1 (en) | 2022-05-11 |
| JP2022512373A (ja) | 2022-02-03 |
| CN113166151A (zh) | 2021-07-23 |
| US20200190093A1 (en) | 2020-06-18 |
| ES2964630T3 (es) | 2024-04-08 |
| EA202191588A1 (ru) | 2021-10-18 |
| PL3894410T3 (pl) | 2024-03-18 |
| US20220177479A1 (en) | 2022-06-09 |
| JP7502299B2 (ja) | 2024-06-18 |
| EP3894410B1 (en) | 2023-10-11 |
| IL283768B1 (en) | 2024-01-01 |
| AU2019396499A1 (en) | 2021-05-27 |
| TW202039495A (zh) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
| CL2019001664A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. | |
| ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| CO2020007244A2 (es) | Inhibidores de kras g12c | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018002410A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| MX2019007156A (es) | Inhibidores de imidazopirazina de la tirosina cinasa de bruton. | |
| CY1123263T1 (el) | Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| MX372716B (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2019015102A2 (es) | Nuevos derivados de xantina sustituidos | |
| CL2021001509A1 (es) | Derivados de xantina sustituida | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CL2021003228A1 (es) | Compuestos tricíclicos y su uso | |
| MX2019014845A (es) | Compuestos de aminotiazol como inhibidores de la proteina quinasa. | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CL2020001252A1 (es) | Métodos de uso y composiciones que contienen dulaglutida. | |
| CL2018002010A1 (es) | Derivados de indano y su uso en terapias. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. |